GILD Gilead Sciences

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • IRA + MFN pricing: Biktarvy selected for Medicare price negotiation effective 2028; Gilead signed Dec 2025 agreement implementing MFN Medicaid prices and pausing Section 232 tariffs for 3 years
• • Pharmaceutical tariff exposure: U.S. administration announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; Gilead sources significant raw materials and intermediates from outside U.S.

Business Overview

• • Biopharmaceutical company focused on HIV, viral hepatitis, COVID-19, and oncology; commercial portfolio of 25+ therapies distributed across 35+ countries via wholesale channel (~90% of U.S. sales through 3 wholesalers)
• • Yeztugo/Yeytuo (lenacapavir) approved as first and only twice-yearly HIV PrEP option in both U.S. and EU; multiple BLA filings pending for anitocabtagene autoleucel (multiple myeloma) and expanded Trodelvy indications in TNBC first-line and NSCLC

Management Discussion & Analysis

• • Revenue $29.4B in 2025, up 2% YoY; HIV +6% to $20.8B best performer; Veklury -49% to $911M worst performer
• • Product gross margin 78.4% vs 78.2% (+29 bps); SG&A down 5% to $5.8B; effective tax rate 13.1% vs 30.5%

Risk Factors

• • New regulatory risk: FDA boxed warning (Jan 2024) on CAR T-cell therapies for secondary T-cell malignancies; impacts Yescarta, Tecartus acceptance
• • Updated pricing risk: Inflation Reduction Act effects uncertain; increased Medicare Part D discounts (10%-20%) and rebate obligations starting 2023-2025

Management Discussion & Analysis

• • No specific quarterly revenue or YoY change data provided in the section
• • No profitability or margin figures disclosed for the quarter

What are the latest GILD SEC filings in 2026?

Gilead Sciences (GILD) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did GILD file its most recent 10-K annual report?

Gilead Sciences (GILD) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view GILD 10-Q quarterly reports?

Gilead Sciences (GILD)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every GILD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has GILD filed recently?

Gilead Sciences (GILD)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find GILD insider trading activity (Form 4)?

The most recent GILD Form 4 insider transaction on SignalX was filed on December 1, 2025. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock. SignalX aggregates every GILD Form 4 with transaction code, share count, and price per share.

How often does GILD file with the SEC?

Gilead Sciences (GILD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GILD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Gilead Sciences (GILD).

What is GILD's SEC CIK number?

Gilead Sciences (GILD)'s SEC CIK (Central Index Key) number is 882095. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 882095 to look up all GILD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find GILD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Gilead Sciences (GILD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.